×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALDX – aldeyra therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/24
06:00 pm
aldx
Pomerantz LLP Notifies Investors of Class Action Against Aldeyra Therapeutics, Inc. – ALDX
Low
Report
Pomerantz LLP Notifies Investors of Class Action Against Aldeyra Therapeutics, Inc. – ALDX
4/24
12:35 pm
aldx
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
Low
Report
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
4/24
10:50 am
aldx
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
4/24
09:00 am
aldx
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Securities Class Action - Contact The Gross Law Firm
Medium
Report
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Securities Class Action - Contact The Gross Law Firm
4/24
07:00 am
aldx
Pomerantz LLP Issues Reminder to Investors in Aldeyra Therapeutics, Inc. of Class Action Lawsuit – ALDX
Medium
Report
Pomerantz LLP Issues Reminder to Investors in Aldeyra Therapeutics, Inc. of Class Action Lawsuit – ALDX
4/24
07:00 am
aldx
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Medium
Report
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
4/23
09:20 pm
aldx
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Medium
Report
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
4/23
07:30 pm
aldx
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:16 pm
ALDX
aldeyra therapeutics, inc.
BEAT
Report
-2.4%
aldeyra therapeutics, inc.
8/7/2025
04:03 pm
ALDX
aldeyra therapeutics, inc.
BEAT
Report
1.7%
aldeyra therapeutics, inc.
5/14/2025
05:13 pm
ALDX
aldeyra therapeutics, inc.
BEAT
Report
1.9%
aldeyra therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/20
05:00 pm
aldx
Form 8-K Aldeyra Therapeutics, For: Apr 20
Medium
Report
Form 8-K Aldeyra Therapeutics, For: Apr 20
4/1
04:25 pm
aldx
Form 8-K Aldeyra Therapeutics, For: Apr 01
Low
Report
Form 8-K Aldeyra Therapeutics, For: Apr 01
3/31
04:18 pm
aldx
Form 4 Aldeyra Therapeutics, For: Mar 27 Filed by: Brady Todd C
Low
Report
Form 4 Aldeyra Therapeutics, For: Mar 27 Filed by: Brady Todd C
3/26
03:26 pm
aldx
Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: VANGUARD GROUP INC
Medium
Report
Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: VANGUARD GROUP INC
3/20
04:18 pm
aldx
Form 4 Aldeyra Therapeutics, For: Mar 19 Filed by: DOUGLAS RICHARD
High
Report
Form 4 Aldeyra Therapeutics, For: Mar 19 Filed by: DOUGLAS RICHARD
3/19
05:29 pm
aldx
Form 4 Aldeyra Therapeutics, For: Mar 18 Filed by: Alfieri Michael
Medium
Report
Form 4 Aldeyra Therapeutics, For: Mar 18 Filed by: Alfieri Michael
3/17
08:39 am
aldx
Form 8-K Aldeyra Therapeutics, For: Mar 17
Low
Report
Form 8-K Aldeyra Therapeutics, For: Mar 17
2/27
05:07 pm
aldx
Form S-8 Aldeyra Therapeutics,
Medium
Report
Form S-8 Aldeyra Therapeutics,
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
27.8%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
1/15 Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy 4.2%
TOP News Decliners
12/3
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
-40.4%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
4/30 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: